Mesh : Aspirin / adverse effects pharmacokinetics therapeutic use Cilostazol Dipyridamole / adverse effects pharmacokinetics therapeutic use Dose-Response Relationship, Drug Drug Therapy, Combination Evidence-Based Medicine Humans Platelet Activation / drug effects Platelet Aggregation / drug effects Platelet Aggregation Inhibitors / adverse effects pharmacokinetics therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors Practice Guidelines as Topic Randomized Controlled Trials as Topic Societies, Medical Tetrazoles / adverse effects pharmacokinetics therapeutic use Thienopyridines / adverse effects pharmacokinetics therapeutic use Thrombosis / blood drug therapy prevention & control United States

来  源:   DOI:10.1378/chest.11-2293

Abstract:
The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa antagonists. The relationships among dose, efficacy, and safety are discussed along with a mechanistic overview of results of randomized clinical trials. The article does not provide specific management recommendations but highlights important practical aspects of antiplatelet therapy, including optimal dosing, the variable balance between benefits and risks when antiplatelet therapies are used alone or in combination with other antiplatelet drugs in different clinical settings, and the implications of persistently high platelet reactivity despite such treatment.
摘要:
暂无翻译
公众号